LncRNA GATA3‐AS1 facilitates tumour progression and immune escape in triple‐negative breast cancer through destabilization of GATA3 but stabilization of PD‐L1

Zhang, Ming; Wang, Ning; Song, Peng; Fu, Yingqiang; Ren, Yanlv; Li, Zhigao; Wang, Jinsong

doi:10.1111/cpr.12855

Cited by 129 publications

(107 citation statements)

References 34 publications

Supporting

Mentioning

105

Contrasting

Unclassified

Order By: Relevance

“…However, the edge of GATA3−AS1 and HDAC7 had a significant correlation difference in several early response cells. GATA3 – AS1 has been reported to be involved in triple-negative breast cancer progression and immune escape by stabilizing the PD-L1 protein and degrading the GATA3 protein ( 27 ). In contrast, the edge of AATF and ERLIN2 showed no correlation difference in early response cells but had a correlation difference in other cells.…”

Section: Discussionmentioning

confidence: 99%

Inferring Cell Subtypes and LncRNA Function by a Cell-Specific CeRNA Network in Breast Cancer

Chen

Zeng

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Single-cell RNA sequencing is a powerful tool to explore the heterogeneity of breast cancer. The identification of the cell subtype that responds to estrogen has profound significance in breast cancer research and treatment. The transcriptional regulation of estrogen is an intricate network involving crosstalk between protein-coding and non-coding RNAs, which is still largely unknown, particularly at the single cell level. Therefore, we proposed a novel strategy to specify cell subtypes based on a cell-specific ceRNA network (CCN). The CCN was constructed by integrating a cell-specific RNA-RNA co-expression network (RCN) with an existing ceRNA network. The cell-specific RCN was built based on single cell expression profiles with predefined reference cells. Heterogeneous cell subtypes were inferred by enriching RNAs in CCN to the estrogen response hallmark. Edge biomarkers were identified in the early estrogen response subtype. Topological analysis revealed that NEAT1 was a hub lncRNA for the early response subtype, and its ceRNAs could predict patient survival. Another hub lncRNA, DLEU2, could potentially be involved in GPCR signaling, based on CCN. The CCN method that we proposed here facilitates the inference of cell subtypes from a network perspective and explores the function of hub lncRNAs, which are promising targets for RNA-based therapeutics.

show abstract

Section: Discussionmentioning

confidence: 99%

Inferring Cell Subtypes and LncRNA Function by a Cell-Specific CeRNA Network in Breast Cancer

Chen

Zeng

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…MIR17HG directly binds to PD-L1 and stabilizes the PD-L1 protein in CRC ( 43 ). A novel lncRNA GATA3-AS1 can also stabilize PD-L1 protein by preventing PD-L1 ubiquitination by means of the miR-676-3p/COPS5 axis in TNBC ( 44 ).…”

Section: Regulation Of Pd-l1 Expressionmentioning

confidence: 99%

Current understanding of cancer-intrinsic PD-L1: regulation of expression and its protumoral activity

Yadollahi

Jeon

et al. 2021

BMB Rep.

View full text Add to dashboard Cite

In the last decade, we have witnessed an unprecedented clinical success in cancer immunotherapies targeting the programmed cell-death ligand 1 (PD-L1) and programmed cell-death 1 (PD-1) pathway. Besides the fact that PD-L1 plays a key role in immune regulation in tumor microenvironment, recently a plethora of reports has suggested a new perspective of non-immunological functions of PD-L1 in the regulation of cancer intrinsic activities including mesenchymal transition, glucose and lipid metabolism, stemness, and autophagy. Here we review the current understanding on the regulation of expression and intrinsic protumoral activity of cancer-intrinsic PD-L1.

show abstract

“…For instance, the HCC-derived exosomal lncRNA TUC339 affected the complicated immune microenvironmental interaction between tumor and immune cells by regulating the polarization of M1/M2 macrophages (16). Besides, lncRNA GATA3-AS1 promoted tumor development and immune escape in triple negative breast cancer by destabilizing GATA3 but stabilizing PD-L1 (17). Thus, it is essential to develop an expression profile based on immune-related lncRNAs that can predict the prognosis of LUAD patients and further guide appropriate individualized treatment strategies.…”

Section: Introductionmentioning

confidence: 99%

An Immune-Related lncRNA Expression Profile to Improve Prognosis Prediction for Lung Adenocarcinoma: From Bioinformatics to Clinical Word

Zhang

Wang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

BackgroundLung cancer is still the top-ranked cancer-related deaths all over the world. Now immunotherapy has emerged as a promising option for treating lung cancer. Recent evidence indicated that lncRNAs were also key regulators in immune system. We aimed to develop a novel prognostic signature based on the comprehensive analysis of immune-related lncRNAs to predict survival outcome of LUAD patients.MethodsThe gene expression profiles of 491 LUAD patients were downloaded from TCGA. 1047 immune-related lncRNAs were obtained through Pearson correlation analysis of immune genes and lncRNAs using statistical software R language. Univariate and multivariate Cox regression analysis were performed to determine the optimal immune-related lncRNAs prognostic signature (ITGCB-DT, ABALON, TMPO-AS1 and VIM-AS1). Finally, we validated the immune-related lncRNAs prognostic signature in The First Affiliated Hospital of Xi’an Jiaotong University cancer center cohort.ResultsA four immune-related lncRNAs prognostic signature was constructed to predict the survival outcome of LUAD patients. Statistical significance were found that the LUAD patients in high-risk group suffered shorter overall survival than those in low-risk group (P <0.001). ROC curve analysis shown that the four immune-related lncRNAs prognostic signature had the best predictive effect compared with age, gender, AJCC-stage, T stage, N stage, M stage (AUC = 0.756). More importantly, clinical cohort studies proved that the signature could predict the overall survival of LUAD patients with an AUC = 0.714.ConclusionsIn summary, we demonstrated that the novel immune-related lncRNAs signature had the ability to predict the prognosis of LUAD patients, which might serve as potential prognostic biomarkers and guide the individualized treatment strategies for LUAD patients.

show abstract

LncRNA GATA3‐AS1 facilitates tumour progression and immune escape in triple‐negative breast cancer through destabilization of GATA3 but stabilization of PD‐L1

Cited by 129 publications

References 34 publications

Inferring Cell Subtypes and LncRNA Function by a Cell-Specific CeRNA Network in Breast Cancer

Inferring Cell Subtypes and LncRNA Function by a Cell-Specific CeRNA Network in Breast Cancer

Current understanding of cancer-intrinsic PD-L1: regulation of expression and its protumoral activity

An Immune-Related lncRNA Expression Profile to Improve Prognosis Prediction for Lung Adenocarcinoma: From Bioinformatics to Clinical Word

Contact Info

Product

Resources

About